Renata C. Bonadio

Sao Paulo, SP 04501000, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: May 21, 2026

Antibody-drug conjugates in platinum-sensitive ovarian cancer: beyond interval-based treatment selection?

Antibody-drug conjugates in platinum-sensitive ovarian cancer: beyond interval-based treatment selection?

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 14, 2026

Role of dynamic ctDNA monitoring in cervical and anal epidermoid carcinomas under curative chemoradiation.

Role of dynamic ctDNA monitoring in cervical and anal epidermoid carcinomas under curative chemoradiation.

Journal: Clinics (Sao Paulo, Brazil)

Published: March 09, 2026

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Journal: JCO oncology practice

Published: March 06, 2026

Toxicity profile and tolerability of immune checkpoint inhibitors for the treatment of early-stage breast cancer: a systematic review and meta-analysis.

Toxicity profile and tolerability of immune checkpoint inhibitors for the treatment of early-stage breast cancer: a systematic review and meta-analysis.

Journal: Breast (Edinburgh, Scotland)

Published: February 11, 2026

Ensemble machine learning for predicting breast cancer recurrence and mortality using clinical and hemogram data.

Ensemble machine learning for predicting breast cancer recurrence and mortality using clinical and hemogram data.

Journal: NPJ breast cancer

Published: December 16, 2025

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Journal: Breast cancer research and treatment

Published: November 22, 2025

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

Journal: NPJ breast cancer

Published: November 02, 2025

Reply letter: Pathologic complete response in TNBC: A shield against recurrence, but not the brain?

Reply letter: Pathologic complete response in TNBC: A shield against recurrence, but not the brain?

Journal: Breast (Edinburgh, Scotland)

Published: September 18, 2025

Immunotherapy in gynecologic clear cell carcinomas: moving beyond conventional approaches.

Immunotherapy in gynecologic clear cell carcinomas: moving beyond conventional approaches.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 17, 2025

When the blood speaks first: circulating tumor DNA as a biomarker in locally advanced cervical cancer.

When the blood speaks first: circulating tumor DNA as a biomarker in locally advanced cervical cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 16, 2025

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Journal: Breast (Edinburgh, Scotland)

Published: May 04, 2025

Showing 1-12 of 53

Last Updated: 09/26/2026